Short-interference RNAs: Becoming medicines

EXCLI Journal

Volumn 14, Issue , 2015, Pages 714-746

  Martínez, Tamara ^a   Jiménez, Ana Isabel ^a   Pañeda, Covadonga ^a  

^a Sylentis SAU   (Spain)

Author keywords

Oligonucleotides; RNAi; siRNA; Therapeutics

Indexed keywords

AGENTS ACTING ON THE EYE; AGENTS AFFECTING PROTEIN METABOLISM; ALN PCS02; ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; ARC 520; ATU 027; DERMATOLOGICAL AGENT; DYNAMIC POLYCONJUGATE; KEXIN; KEXIN TYPE 9; MACROGOL; ND L02 S0201; OLIGONUCLEOTIDE; PATISIRAN; PHOSPHOROTHIOIC ACID; POLO LIKE KINASE; POLYMER; PREALBUMIN; QPI 007; QPI 1002; REVUSIRAN; RXI 109; SMALL INTERFERING RNA; SOLID LIPID NANOPARTICLE; SYL 1001; TKM EBOLA; TKM PKL1; TMK APOB; UNCLASSIFIED DRUG;

ARTICLE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG INDUSTRY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EXAGGERATED PHARMACOLOGY; EYE; FAMILIAL AMYLOID POLYNEUROPATHY; FAMILIAL AMYLOIDOSIS; FAMILIAL AMYLOIDOTIC CARDIOPATHY; GENE DELIVERY SYSTEM; GENE TARGETING; GENE THERAPY; HUMAN; IMMUNOMODULATION; ISCHEMIC HEART DISEASE; KIDNEY; KIDNEY DISEASE; LIVER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; NUCLEIC ACID BASE SUBSTITUTION; OFF TARGET EFFECT; PHARMACOLOGICAL PARAMETERS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RNA HYBRIDIZATION; RNA INTERFERENCE; RNA STABILITY; SKIN; SOLID TUMOR; VASCULAR ENDOTHELIUM; VIRUS INFECTION;

EID: 84935005894     PISSN: None     EISSN: 16112156     Source Type: Journal    
DOI: 10.17179/excli2015-297     Document Type: Article

References (145)

1. Ahmed Z, Kalinski H, Berry M, Almasieh M, Ashush H, Slager N, et al. Ocular neuroprotection by siRNA targeting caspase-2. Cell Death Dis. 2011;2:e173
2. Akinc A, Querbes W, De S, Qin J, Frank-Kamenetsky M, Jayaprakash KN, et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligandbased mechanisms. Mol Ther. 2010;18:1357-64
3. Allerson CR, Sioufi N, Jarres R, Prakash TP, Naik N, Berdeja A, et al. Fully 2'-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J Med Chem. 2005;48:901-4
4. Amarzguioui M, Holen T, Babaie E, Prydz H. Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res. 2003;31:589-95
5. Arthur MJ. Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology. 2002;122:1525-8
6. Baluk P, Hashizume H, McDonald DM. Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev. 2005;15:102-11
7. Barros SA, Gollob JA. Safety profile of RNAi nanomedicines. Adv Drug Deliv Rev. 2012;64:1730-7
8. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281-97
9. Bartlett DW, Su H, Hildebrandt IJ, Weber WA, Davis ME. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA. 2007;104:15549-54
10. Berman CL, Cannon K, Cui Y, Kornbrust DJ, Lagrutta A, Sun SZ, et al. Recommendations for safety pharmacology evaluations of oligonucleotidebased therapeutics. Nucleic Acid Ther. 2014;24:291-301
11. Bertrand JR, Pottier M, Vekris A, Opolon P, Maksimenko A, Malvy C. Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem Biophys Res Commun. 2002;296:1000-4
12. Birmingham A, Anderson EM, Reynolds A, Ilsley-Tyree D, Leake D, Fedorov Y, et al. 3' UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat Methods. 2006;3:199-204
13. Bisanz K, Yu J, Edlund M, Spohn B, Hung MC, Chung LW, et al. Targeting ECM-integrin interaction with liposome-encapsulated small interfering RNAs inhibits the growth of human prostate cancer in a bone xenograft imaging model. Mol Ther. 2005;12:634-43
14. Black LE, Farrelly JG, Cavagnaro JA, Ahn CH, DeGeorge JJ, Taylor AS, et al. Regulatory considerations for oligonucleotide drugs: updated recommendations for pharmacology and toxicology studies. Antisense Res Dev. 1994;4:299-301
15. Boudreau RL, Rodriguez-Lebron E, Davidson BL. RNAi medicine for the brain: progresses and challenges. Hum Mol Genet. 2011;20:R21-7
16. Bramsen JB, Kjems J. Chemical modification of small interfering RNA. Methods Mol Biol. 2011;721:77-103
17. Bramsen JB, Kjems J. Engineering small interfering RNAs by strategic chemical modification. Methods Mol Biol. 2013;942:87-109
18. Bramsen JB, Pakula MM, Hansen TB, Bus C, Langkjaer N, Odadzic D, et al. A screen of chemical modifications identifies position-specific modification by UNA to most potently reduce siRNA off-target effects. Nucleic Acids Res. 2010;38:5761-73
19. Burdick AD, Sciabola S, Mantena SR, Hollingshead BD, Stanton R, Warneke JA, et al. Sequence motifs associated with hepatotoxicity of locked nucleic acid--modified antisense oligonucleotides. Nucleic Acids Res. 2014;42:4882-91
20. Burnett JC, Rossi JJ. RNA-based therapeutics: current progress and future prospects. Chem Biol. 2012;19: 60-71
21. Byrne M, Tzekov R, Wang Y, Rodgers A, Cardia J, Ford G, et al. Novel hydrophobically modified asymmetric RNAi compounds (sd-rxRNA) demonstrate robust efficacy in the eye. J Ocul Pharmacol Ther. 2013;29:855-64
22. Chang CI, Yoo JW, Hong SW, Lee SE, Kang HS, Sun X, et al. Asymmetric shorter-duplex siRNA structures trigger efficient gene silencing with reduced nonspecific effects. Mol Ther. 2009;17:725-32
23. Chen JK, Schultz RG, Lloyd DH, Gryaznov SM. Synthesis of oligodeoxyribonucleotide N3'-->P5' phosphoramidates. Nucleic Acids Res. 1995;23:2661-8
24. Cheng A, Li M, Liang Y, Wang Y, Wong L, Chen C, et al. Stem-loop RT-PCR quantification of siRNAs in vitro and in vivo. Oligonucleotides. 2009;19:203-8
25. Chiu YL, Rana TM. siRNA function in RNAi: a chemical modification analysis. RNA. 2003;9:1034-48
26. Chong RH, Gonzalez-Gonzalez E, Lara MF, Speaker TJ, Contag CH, Kaspar RL, et al. Gene silencing following siRNA delivery to skin via coated steel microneedles: In vitro and in vivo proof-of-concept. J Control Release. 2013;166:211-9
27. Chu CY, Rana TM. Potent RNAi by short RNA triggers. RNA. 2008;14:1714-9
28. Coch C, Luck C, Schwickart A, Putschli B, Renn M, Holler T, et al. A human in vitro whole blood assay to predict the systemic cytokine response to therapeutic oligonucleotides including siRNA. PLoS One. 2013; 8:e71057
29. Coelho T, Adams D, Silva A, Lozeron P, Hawkins PN, Mant T, et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. N Engl J Med. 2013;369:819-29
30. Cohen JC, Boerwinkle E, Mosley TH Jr., Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264-72
31. Colacino JM, Horn JW, Horn DM, Richardson FC. Incorporation of fialuridine (FIAU) into mitochondrial DNA and effects of FIAU on the morphology of mitochondria in human hepatoblastoma cells. Toxicol In Vitro. 1996;10:297-303
32. Czauderna F, Fechtner M, Dames S, Aygun H, Klippel A, Pronk GJ, et al. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res. 2003;31:2705-16
33. Dande P, Prakash TP, Sioufi N, Gaus H, Jarres R, Berdeja A, et al. Improving RNA interference in mammalian cells by 4'-thio-modified small interfering RNA (siRNA): effect on siRNA activity and nuclease stability when used in combination with 2'-O-alkyl modifications. J Med Chem. 2006;49:1624-34
34. Deleavey GF, Watts JK, Damha MJ. Chemical modification of siRNA. Curr Protoc Nucleic Acid Chem. 2009;39(16.3):1-22
35. Demidov VV, Potaman VN, Frank-Kamenetskii MD, Egholm M, Buchard O, Sonnichsen SH, et al. Stability of peptide nucleic acids in human serum and cellular extracts. Biochem Pharmacol. 1994;48:1310-3
36. Diebold SS, Massacrier C, Akira S, Paturel C, Morel Y, Reis e Sousa C. Nucleic acid agonists for Toll-like receptor 7 are defined by the presence of uridine ribonucleotides. Eur J Immunol. 2006;36:3256-67
37. Dowler T, Bergeron D, Tedeschi AL, Paquet L, Ferrari N, Damha MJ. Improvements in siRNA properties mediated by 2'-deoxy-2'-fluoro-beta-Darabinonucleic acid (FANA). Nucleic Acids Res. 2006;34:1669-75
38. Eckstein F. Developments in RNA chemistry, a personal view. Biochimie. 2002;84:841-8
39. Eckstein F. Phosphorothioates, essential components of therapeutic oligonucleotides. Nucleic Acid Ther. 2014;24:374-87
40. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001a;411:494-8
41. Elbashir SM, Martinez J, Patkaniowska A, Lendeckel W, Tuschl T. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J. 2001b;20:6877-88
42. Elmen J, Thonberg H, Ljungberg K, Frieden M, Westergaard M, Xu Y, et al. Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality. Nucleic Acids Res. 2005;33:439-47
43. European Medicines Agency. CHMP SWP reflection paper on the assessment of the genotoxic potential of antisense oligonucleotides, EMEA/CHMP/SWP/ 199726/2004, 2005, London. http://www.ema.europa.eu/docs/en_GB/document_lib rary/Scientific_guideline/2009/09/WC500003149.pdf
44. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 1998;391:806-11
45. Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, Liebow A, Bettencourt BR, Sutherland JE, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial. Lancet. 2013; 383:60-8
46. Flatekval GF, Sioud M. Modulation of dendritic cell maturation and function with mono-and bifunctional small interfering RNAs targeting indoleamine 2,3-dioxygenase. Immunology. 2009;128:e837-48
47. Galbraith WM, Hobson WC, Giclas PC, Schechter PJ, Agrawal S. Complement activation and hemodynamic changes following intravenous administration of phosphorothioate oligonucleotides in the monkey. Antisense Res Dev. 1994;4:201-6
48. Geisbert TW, Lee AC, Robbins M, Geisbert JB, Honko AN, Sood V, et al. Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study. Lancet. 2010;375:1896-905
49. Goodchild A, Nopper N, King A, Doan T, Tanudji M, Arndt GM, et al. Sequence determinants of innate immune activation by short interfering RNAs. BMC Immunol. 2009;10:40
50. Guga P, Stec WJ. Synthesis of phosphorothioate oligonucleotides with stereodefined phosphorothioate linkages. Curr Protoc Nucleic Acid Chem. 2003;4:4 17
51. Hall AH, Wan J, Shaughnessy EE, Ramsay Shaw B, Alexander KA. RNA interference using boranophosphate siRNAs: structure-activity relationships. Nucleic Acids Res. 2004;32:5991-6000
52. Henry SP, Giclas PC, Leeds J, Pangburn M, Auletta C, Levin AA, et al. Activation of the alternative pathway of complement by a phosphorothioate oligonucleotide: potential mechanism of action. J Pharmacol Exp Ther. 1997;281:810-6
53. Henry SP, Beattie G, Yeh G, Chappel A, Giclas P, Mortari A, et al. Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide. Int Immunopharmacol. 2002;2:1657-66
54. Henry SP, Jagels MA, Hugli TE, Manalili S, Geary RS, Giclas PC, et al. Mechanism of alternative complement pathway dysregulation by a phosphorothioate oligonucleotide in monkey and human serum. Nucleic Acid Ther. 2014;24:326-35
55. Hermansen LF, Bergman T, Jornvall H, Husby G, Ranlov I, Sletten K. Purification and characterization of amyloid-related transthyretin associated with familial amyloidotic cardiomyopathy. Eur J Biochem. 1995;227:772-9
56. Holen T, Amarzguioui M, Wiiger MT, Babaie E, Prydz H. Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor. Nucleic Acids Res. 2002;30:1757-66
57. Hornung V, Barchet W, Schlee M, Hartmann G. RNA recognition via TLR7 and TLR8. Handb Exp Pharmacol. 2008;183:71-86
58. Hou X, Aguilar MI, Small DH. Transthyretin and familial amyloidotic polyneuropathy. Recent progress in understanding the molecular mechanism of neurodegeneration. FEBS J. 2007;274:1637-50
59. Jackson AL, Burchard J, Schelter J, Chau BN, Cleary M, Lim L, et al. Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA. 2006;12:1179-87
60. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human MicroRNA targets. PLoS Biol. 2004;2:e363
61. Johnson AA, Ray AS, Hanes J, Suo Z, Colacino JM, Anderson KS, et al. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J Biol Chem. 2001;276:40847-57
62. Judge AD, Sood V, Shaw JR, Fang D, McClintock K, MacLachlan I. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol. 2005;23:457-62
63. Judge AD, Robbins M, Tavakoli I, Levi J, Hu L, Fronda A, et al. Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest. 2009;119:661-73
64. Juliano RL, Ming X, Carver K, Laing B. Cellular uptake and intracellular trafficking of oligonucleotides: implications for oligonucleotide pharmacology. Nucleic Acid Ther. 2014;24:101-13
65. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature. 2006;441:101-5
66. Kigasawa K, Kajimoto K, Hama S, Saito A, Kanamura K, Kogure K. Noninvasive delivery of siRNA into the epidermis by iontophoresis using an atopic dermatitis-like model rat. Int J Pharm. 2010;383:157-60
67. Kleinman ME, Yamada K, Takeda A, Chandrasekaran V, Nozaki M, Baffi JZ, et al. Sequence-and target-independent angiogenesis suppression by siRNA via TLR3. Nature. 2008;452:591-7
68. Klingelhoefer JW, Moutsianas L, Holmes C. Approximate Bayesian feature selection on a large meta-dataset offers novel insights on factors that effect siRNA potency. Bioinformatics. 2009;25:1594-601
69. Kornbrust D, Cavagnaro J, Levin A, Foy J, Pavco P, Gamba-Vitalo C, et al. Oligo safety working group exaggerated pharmacology subcommittee consensus document. Nucleic Acid Ther. 2013;23:21-8
70. Koshkin AA, Wengel J. Synthesis of novel 2',3'-linked bicyclic thymine ribonucleosides. J Org Chem. 1998;63:2778-81
71. Lara MF, Gonzalez-Gonzalez E, Speaker TJ, Hickerson RP, Leake D, Milstone LM, et al. Inhibition of CD44 gene expression in human skin models, using self-delivery short interfering RNA administered by dissolvable microneedle arrays. Hum Gene Ther. 2012;23:816-23
72. Larsson E, Sander C, Marks D. mrna turnover rate limits siRNA and microRNA efficacy. Mol Syst Biol. 2010;6:433
73. Leachman SA, Hickerson RP, Schwartz ME, Bullough EE, Hutcherson SL, Boucher KM, et al. First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Ther. 2010;18: 442-6
74. Lee EW, Lai Y, Zhang H, Unadkat JD. Identification of the mitochondrial targeting signal of the human equilibrative nucleoside transporter 1 (hENT1): implications for interspecies differences in mitochondrial toxicity of fialuridine. J Biol Chem. 2006;281: 16700-6
75. Lee YH, Andersen JB, Song HT, Judge AD, Seo D, Ishikawa T, et al. Definition of ubiquitination modulator COP1 as a novel therapeutic target in human hepatocellular carcinoma. Cancer Res. 2010;70:8264-9
76. Lee YH, Judge AD, Seo D, Kitade M, Gomez-Quiroz LE, Ishikawa T, et al. Molecular targeting of CSN5 in human hepatocellular carcinoma: a mechanism of therapeutic response. Oncogene. 2011;30:4175-84
77. Levin AA. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim Biophys Acta. 1999;1489: 69-84
78. Levin AA, Henry SP. Toxicology of oligonucleotide therapeutics and understanding the relevance of the toxicities. In: Cavagnaro JA (ed.): Preclinical safety evaluation of biopharmaceuticals: A science-based approach to facilitating clinical trials (pp 537-75). Hoboken, NJ: Wiley, 2008
79. Lewis W, Levine ES, Griniuviene B, Tankersley KO, Colacino JM, Sommadossi JP, et al. Fialuridine and its metabolites inhibit DNA polymerase gamma at sites of multiple adjacent analog incorporation, decrease mtDNA abundance, and cause mitochondrial structural defects in cultured hepatoblasts. Proc Natl Acad Sci USA. 1996;93:3592-7
80. Lindow M, Vornlocher HP, Riley D, Kornbrust DJ, Burchard J, Whiteley LO, et al. Assessing unintended hybridization-induced biological effects of oligonucleotides. Nat Biotechnol. 2012;30:920-3
81. Liu Q, Zhou H, Zhang K, Shi X, Fan W, Zhu R, et al. In silico target-specific siRNA design based on domain transfer in heterogeneous data. PLoS One. 2012;7:e50697
82. Lombardo A, Genovese P, Beausejour CM, Colleoni S, Lee YL, Kim KA, et al. Gene editing in human stem cells using zinc finger nucleases and integrasedefective lentiviral vector delivery. Nat Biotechnol. 2007;25:1298-306
83. Lundin KE, Hojland T, Hansen BR, Persson R, Bramsen JB, Kjems J, et al. Biological activity and biotechnological aspects of locked nucleic acids. Adv Genet. 2013;82:47-107
84. Maier MA, Jayaraman M, Matsuda S, Liu J, Barros S, Querbes W, et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol Ther. 2013;21:1570-8
85. Marques JT, Williams BR. Activation of the mammalian immune system by siRNAs. Nat Biotechnol. 2005;23:1399-405
86. Marques JT, Devosse T, Wang D, Zamanian-Daryoush M, Serbinowski P, Hartmann R, et al. A structural basis for discriminating between self and nonself double-stranded RNAs in mammalian cells. Nat Biotechnol. 2006;24:559-65
87. Martinez J, Patkaniowska A, Urlaub H, Luhrmann R, Tuschl T. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell. 2002;110:563-74
88. Martinez T, Wright N, Lopez-Fraga M, Jimenez AI, Paneda C. Silencing human genetic diseases with oligonucleotide-based therapies. Hum Genet. 2013;132: 481-93
89. Martinez T, Gonzalez MV, Roehl I, Wright N, Paneda C, Jimenez AI. In vitro and in vivo efficacy of SYL040012, a novel siRNA compound for treatment of glaucoma. Mol Ther. 2014;22:81-91
90. Martinez-Garcia MC, Martinez T, Paneda C, Gallego P, Jimenez AI, Merayo J. Differential expression and localization of transient receptor potential vanilloid 1 in rabbit and human eyes. Histol Histopathol. 2013; 28:1507-16
91. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med. 1995;333:1099-105
92. Meurs E, Chong K, Galabru J, Thomas NS, Kerr IM, Williams BR, et al. Molecular cloning and characterization of the human double-stranded RNAactivated protein kinase induced by interferon. Cell. 1990;62: 379-90
93. Moreno-Montanes J, Sadaba B, Ruz V, Gomez-Guiu A, Zarranz J, Gonzalez MV, et al. Phase I clinical trial of SYL040012, a small interfering RNA targeting beta-adrenergic receptor 2, for lowering intraocular rressure. Mol Ther. 2014;22:226-32
94. Morrissey DV, Lockridge JA, Shaw L, Blanchard K, Jensen K, Breen W, et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol. 2005;23:1002-7
95. Moulton JD, Jiang S. Gene knockdowns in adult animals: PPMOs and vivo-morpholinos. Molecules. 2009;14:1304-23
96. Nagata K. Hsp47: a collagen-specific molecular chaperone. Trends Biochem Sci. 1996;21:22-6
97. Nair JK, Willoughby JL, Chan A, Charisse K, Alam MR, Wang Q, et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc. 2014;136:16958-61
98. Nakai N, Kishida T, Shin-Ya M, Imanishi J, Ueda Y, Kishimoto S, et al. Therapeutic RNA interference of malignant melanoma by electrotransfer of small interfering RNA targeting Mitf. Gene Ther. 2007;14:357-65
99. Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AP. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov. 2006;5:123-32
100. Nykanen A, Haley B, Zamore PD. ATP requirements and small interfering RNA structure in the RNA interference pathway. Cell. 2001;107:309-21
101. Pañeda C. SYL040012, a siRNA for the treatment of glaucoma. Acta Ophthalmologica. 2013;91. doi: 10.1111/j.1755-3768.2013.4227.x.
102. Pañeda C, Martínez T, Wright N, Jiménez AI. Recent advances in ocular nucleic acid-based therapies: the silent era. In: Aio A (ed.): Ocular diseases (pp 157-86). Rijeka, Croatia: InTech, 2012
103. Pañeda C, Gonzalez V, Martínez T, Ruz V, Vargas B, Jiménez AI. RNAi based therapies for ocular conditions. In: Proceedings of the 11th ISOPT, Bologna, Italy (pp 25-30). Bologna: Medimond, 2014
104. Parkin J, Cohen B. An overview of the immune system. Lancet. 2001;357:1777-89
105. Patel DJ, Ma JB, Yuan YR, Ye K, Pei Y, Kuryavyi V, et al. Structural biology of RNA silencing and its functional implications. Cold Spring Harb Symp Quant Biol. 2006;71:81-93
106. Peacock H, Kannan A, Beal PA, Burrows CJ. Chemical modification of siRNA bases to probe and enhance RNA interference. J Org Chem. 2011;76:7295-300
107. Pei Y, Tuschl T. On the art of identifying effective and specific siRNAs. Nat Methods. 2006;3:670-6
108. Plenge RM, Scolnick EM, Altshuler D. Validating therapeutic targets through human genetics. Nat Rev Drug Discov. 2013;12:581-94
109. Prakash TP, Allerson CR, Dande P, Vickers TA, Sioufi N, Jarres R, et al. Positional effect of chemical modifications on short interference RNA activity in mammalian cells. J Med Chem. 2005;48:4247-53
110. Puri N, Wang X, Varma R, Burnett C, Beauchamp L, Batten DM, et al. LNA incorporated siRNAs exhibit lower off-target effects compared to 2'-OMethoxy in cell phenotypic assays and microarray analysis. Nucleic Acids Symp Ser (Oxf). 2008:25-6
111. Reynolds A, Leake D, Boese Q, Scaringe S, Marshall WS, Khvorova A. Rational siRNA design for RNA interference. Nat Biotechnol. 2004;22:326-30
112. Rozema DB, Lewis DL, Wakefield DH, Wong SC, Klein JJ, Roesch PL, et al. Dynamic PolyConjugates for targeted in vivo delivery of siRNAs to hepatocytes. Proc Natl Acad SciUSA. 2007;104:12982-7
113. Samuel CE. Antiviral actions of interferons. Clin Microbiol Rev. 2001;14:778-809
114. Sanchez A, Kiley MP, Holloway BP, Auperin DD. Sequence analysis of the Ebola virus genome: organization, genetic elements, and comparison with the genome of Marburg virus. Virus Res. 1993;29:215-40
115. Sanghvi YS. A status update of modified oligonucleotides for chemotherapeutics applications. Curr Protoc Nucleic Acid Chem. 2011;4(4.1):1-22
116. Santel A, Aleku M, Keil O, Endruschat J, Esche V, Fisch G, et al. A novel siRNA-lipoplex technology for RNA interference in the mouse vascular endothelium. Gene Ther. 2006;13:1222-34
117. Sato Y, Murase K, Kato J, Kobune M, Sato T, Kawano Y, et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol. 2008; 26:431-42
118. Schwarz DS, Hutvagner G, Du T, Xu Z, Aronin N, Zamore PD. Asymmetry in the assembly of the RNAi enzyme complex. Cell. 2003;115:199-208
119. Seymour LW. Passive tumor targeting of soluble macromolecules and drug conjugates. Crit Rev Ther Drug Carrier Syst. 1992;9:135-87
120. Sheehan D, Lunstad B, Yamada CM, Stell BG, Caruthers MH, Dellinger DJ. Biochemical properties of phosphonoacetate and thiophosphonoacetate oligodeoxyribonucleotides. Nucleic Acids Res. 2003;31: 4109-18
121. Sioud M. Innate sensing of self and non-self RNAs by Toll-like receptors. Trends Mol Med. 2006a;12:167-76
122. Sioud M. Single-stranded small interfering RNA are more immunostimulatory than their double-stranded counterparts: a central role for 2'-hydroxyl uridines in immune responses. Eur J Immunol. 2006b;36:1222-30
123. Sioud M. Overcoming the challenges of siRNA activation of innate immunity: design better therapeutic siRNAs. Methods Mol Biol. 2015;1218:301-19
124. Solano EC, Kornbrust DJ, Beaudry A, Foy JW, Schneider DJ, Thompson JD. Toxicological and pharmacokinetic properties of QPI-1007, a chemically modified synthetic siRNA targeting caspase 2 mRNA, following intravitreal injection. Nucleic Acid Ther. 2014;24:258-66
125. Sorrentino S. The eight human "canonical" ribonucleases: molecular diversity, catalytic properties, and special biological actions of the enzyme proteins. FEBS Lett. 2010;584:2194-200
126. Soutschek J, Akinc A, Bramlage B, Charisse K, Constien R, Donoghue M, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 2004;432:173-8
127. Stein CA, Hansen JB, Lai J, Wu S, Voskresenskiy A, Hog A, et al. Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res. 2010;38:e3
128. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer. 2006;6:321-30
129. Sun X, Rogoff HA, Li CJ. Asymmetric RNA duplexes mediate RNA interference in mammalian cells. Nat Biotechnol. 2008;26:1379-82
130. Tabernero J, Shapiro GI, LoRusso PM, Cervantes A, Schwartz GK, Weiss GJ, et al. First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement. Cancer Discov. 2013;3:406-17
131. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol. 2005;17:1-14
132. Thompson JD, Kornbrust DJ, Foy JW, Solano EC, Schneider DJ, Feinstein E, et al. Toxicological and Pharmacokinetic Properties of Chemically Modified siRNAs Targeting p53 RNA Following Intravenous Administration. Nucleic Acid Ther. 2012;22:255-64
133. Vaish N, Chen F, Seth S, Fosnaugh K, Liu Y, Adami R, et al. Improved specificity of gene silencing by siRNAs containing unlocked nucleobase analogs. Nucleic Acids Res. 2011;39:1823-32
134. van de Water FM, Boerman OC, Wouterse AC, Peters JG, Russel FG, Masereeuw R. Intravenously administered short interfering RNA accumulates in the kidney and selectively suppresses gene function in renal proximal tubules. Drug Metab Dispos. 2006;34:1393-7
135. Vicentini FT, Borgheti-Cardoso LN, Depieri LV, de Macedo Mano D, Abelha TF, Petrilli R, et al. Delivery systems and local administration routes for therapeutic siRNA. Pharm Res. 2013;30:915-31
136. Wang Y, Sheng G, Juranek S, Tuschl T, Patel DJ. Structure of the guide-strand-containing argonaute silencing complex. Nature. 2008;456:209-13
137. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet. 2004;363:1711-20
138. Wisse E. An electron microscopic study of the fenestrated endothelial lining of rat liver sinusoids. J Ultrastruct Res. 1970;31:125-50
139. Wong SC, Klein JJ, Hamilton HL, Chu Q, Frey CL, Trubetskoy VS, et al. Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterolconjugated small interfering RNAs in vivo. Nucleic Acid Ther. 2012; 22:380-90
140. Wooddell CI, Rozema DB, Hossbach M, John M, Hamilton HL, Chu Q, et al. Hepatocyte-targeted RNAi Therapeutics for the Treatment of Chronic Hepatitis B Virus Infection. Mol Ther. 2013;21:973-85
141. Xiang S, Fruehauf J, Li CJ. Short hairpin RNAexpressing bacteria elicit RNA interference in mammals. Nat Biotechnol. 2006;24:697-702
142. Yang W. Nucleases: diversity of structure, function and mechanism. Q Rev Biophys. 2011;44:1-93
143. Yang C, Zhao T, Zhao Z, Jia Y, Li L, Zhang Y, et al. Serum-stabilized Naked Caspase-3 siRNA Protects Autotransplant Kidneys in a Porcine Model. Mol Ther. 2014;22:1817-28
144. Yu JY, DeRuiter SL, Turner DL. RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc Natl Acad Sci U S A. 2002;99:6047-52
145. Zheng J, Yong HY, Panutdaporn N, Liu C, Tang K, Luo D. High-resolution HDX-MS reveals distinct mechanisms of RNA recognition and activation by RIG-I and MDA5. Nucleic Acids Res. 2015;43:1216-30.